Research brokerages are projecting Halozyme Therapeutics, Inc. (NASDAQ:HALO) to grow at an accelerated rate over the next 5 years. Wall Street analysts are looking for the company to grow -442.90% over the next year and 55.00% over the next five years.
Halozyme Therapeutics, Inc.’s trailing 12- months EPS is -0.68. Last year, their EPS growth was -216.50% and their EPS growth over the past five years was -33.10%.
Let’s start off by taking a look at how the stock has been performing recently. Over the past twelve months, Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s stock was 86.13%. Last week, it was 8.11%, 54.54% over the last quarter, and 26.13% for the past half-year.
Over the past 50 days, Halozyme Therapeutics, Inc. stock was -6.58% off of the high and 44.52% removed from the low. Their 52-Week High and Low are noted here. -6.58% (High), 86.93%, (Low).
Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s performance this year to date is 86.13%. The stock has performed 8.11% over the last seven days, 5.27% over the last thirty, and 54.54% over the last three months. Over the last six months, Halozyme Therapeutics, Inc.’s stock has been 26.13% and 46.18% for the year.
Wall Street analysts are have a consensus analyst recommendation of 2.30 on the stock. This is based on a 1-5 scale where 1 represents a Strong Buy and 5 a Strong Sell. Brokerages covering the name have a $20.60 on the stock.
The advice provided on this website is general advice only. It has been prepared without taking into account your objectives, financial situation or needs. Before acting on this advice you should consider the appropriateness of the advice, having regard to your own objectives, financial situation and needs. Where quoted, past performance is not indicative of future performance.